Morepen Laboratories (MOREPENLAB) Share Price Falls 6.25% Today; Valuation and Sector Context in Focus

Morepen Laboratories Share Price fell to Rs 108.70 on 15 September 2026, down Rs 7.25 or 6.25% from the previous close of Rs 115.95. The move took the company’s market capitalisation to Rs 6,353.52 crore. The stock belongs to the Mid Cap category in the Healthcare sector’s Pharmaceuticals & Drugs industry.

The supplied data confirms the decline, but it does not identify a company-specific catalyst behind it. That makes the available numbers the main basis for analysis. The stock opened at Rs 116.15, touched a high of Rs 116.75, slipped to a low of Rs 104.40, and was trading at Rs 108.70 at the captured time. Turnover stood at Rs 10.05 crore.

For readers tracking today’s move, the main questions are straightforward: how the intraday weakness developed, whether valuation remains demanding relative to industry benchmarks, and how Morepen’s profitability compares with larger pharmaceutical peers. Those three pieces together explain why the stock is drawing attention despite the absence of a stated trigger in the supplied dataset.

Morepen Laboratories (MOREPENLAB) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 108.7
Previous Close	Rs 115.95
Today's Move	-Rs 7.25 (-6.25%)
Open	Rs 116.15
High	Rs 116.75
Low	Rs 104.4
Turnover	Rs 10.05 crore
Market Capitalisation	Rs 6,353.52 crore
Market Cap Category	Mid Cap

The session shows a clear deterioration after a stable start. The stock opened at Rs 116.15, slightly above the previous close of Rs 115.95, and briefly moved up to Rs 116.75. It then weakened sharply to Rs 104.40 before recovering part of the loss to Rs 108.70.

That sequence matters because it shows the decline did not begin with a large weak open. Instead, selling pressure appeared after the stock initially held near the prior closing zone. The spread between the day’s high of Rs 116.75 and low of Rs 104.40 also points to a broad intraday swing.

Turnover of Rs 10.05 crore indicates active trading around the move. In a Mid Cap name, that combination of a sharp decline and a wide range often brings valuation and peer context into focus quickly.

Morepen Laboratories (MOREPENLAB) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 6,353.52 crore
P/E Ratio	45.21x
P/B Ratio	4.88x
ROE	7.96%
ROCE	10.19%
EPS	Rs 2.56
Book Value Per Share	Rs 23.78
Dividend Yield	0.17%

Fundamentally, Morepen Laboratories combines mid-sized market value with valuation multiples that are not low. The company’s market capitalisation is Rs 6,353.52 crore. It trades at a P/E ratio of 45.21 and a P/B ratio of 4.88, while EPS stands at Rs 2.56 and book value per share at Rs 23.78. Dividend yield is 0.17%.

The more important part of the picture is profitability. ROE is 7.96% and ROCE is 10.19%. These figures remain positive, but they are moderate numbers for a stock trading at the above valuation multiples. That does not tell investors whether the stock must move one way or another next, but it does explain why today’s price fall naturally leads to a closer look at sector benchmarks.

In short, the stock is not being evaluated only on the day’s decline. It is also being judged on whether earnings, net worth and returns support the current valuation context.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	45.21x
Benchmark Median P/E	32.72x
Benchmark Average P/E	49.15x
Benchmark P/E Range	3.34x to 693.7x
Company P/B Ratio	4.88x
Benchmark Median P/B	3.05x
Benchmark Average P/B	4.37x
Company ROE	7.96%
Benchmark Median ROE	11.69%
Benchmark Average ROE	10.54%
Company ROCE	10.19%
Benchmark Median ROCE	13.24%
Benchmark Average ROCE	13.09%
Company Market Capitalisation	Rs 6,353.52 crore
Benchmark Median Market Cap	Rs 704.59 crore
Benchmark Average Market Cap	Rs 13,873.11 crore

Morepen operates in the Healthcare sector and specifically in Pharmaceuticals & Drugs. The benchmark set covers 204 companies in the same industry, which makes it a useful reference point for comparing valuation and returns.

On valuation, the company’s P/E of 45.21 is above the industry median of 32.72 but below the average of 49.15. The industry range is very wide, from 3.34 to 693.7 across 169 companies with P/E data. On P/B, Morepen’s 4.88 is above the median of 3.05 and above the average of 4.37 across 203 companies.

Profitability looks less strong against the same benchmark. ROE of 7.96% is below the industry median of 11.69% and average of 10.54%, while ROCE of 10.19% is below the median of 13.24% and average of 13.09%. Market-cap context is mixed: Rs 6,353.52 crore is well above the industry median of Rs 704.59 crore, but below the average of Rs 13,873.11 crore.

Taken together, those benchmarks suggest that valuation is on the firmer side relative to the company’s current return ratios. That is one reason the stock’s decline is being watched closely.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,41,957.5	36.54	5.11	14.85	19.11
Divi's Laboratories	DIVISLAB	2,47,576	84.64	14.02	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,233.01	86.76	21.08	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,11,670.55	24.74	4.14	19.69	21.39
Cipla	CIPLA	1,10,272.68	32.72	3.14	11.83	16

Peer comparison shows that Morepen is much smaller than the large pharmaceutical names in the supplied set. Its market cap of Rs 6,353.52 crore is far below Sun Pharmaceutical Industries at Rs 4,41,957.5 crore, Divi’s Laboratories at Rs 2,47,576 crore, Torrent Pharmaceuticals at Rs 1,89,233.01 crore, Zydus Lifesciences at Rs 1,11,670.55 crore and Cipla at Rs 1,10,272.68 crore.

On valuation, the company’s P/E of 45.21 is higher than Sun Pharma’s 36.54, Zydus’ 24.74 and Cipla’s 32.72, but lower than Divi’s 84.64 and Torrent’s 86.76. Its P/B of 4.88 is near Sun Pharma’s 5.11, above Zydus’ 4.14 and Cipla’s 3.14, and below Divi’s 14.02 and Torrent’s 21.08.

The bigger gap appears in profitability. Morepen’s ROE of 7.96% is below Sun Pharma’s 14.85%, Divi’s 16.19%, Torrent’s 26.76%, Zydus’ 19.69% and Cipla’s 11.83%. Its ROCE of 10.19% is also below all five peers, whose ROCE figures range from 16% to 21.51%.

This does not by itself determine future price direction, but it does show why the stock may face closer scrutiny when it declines sharply.

Why Investors Are Watching Morepen Laboratories

• Sharp daily decline: the stock was down 6.25% at Rs 108.70 versus the previous close of Rs 115.95.
• Wide intraday range: it traded between Rs 116.75 and Rs 104.40 after opening at Rs 116.15.
• Active turnover: trading value stood at Rs 10.05 crore at the captured time.
• Valuation above key medians: P/E of 45.21 and P/B of 4.88 are both above same-industry median levels.
• Profitability below benchmarks: ROE of 7.96% and ROCE of 10.19% trail both industry medians and the supplied large peers.

About Morepen Laboratories

Morepen Laboratories is part of the Healthcare sector and operates in Pharmaceuticals & Drugs. Based on the supplied classification, it is currently a Mid Cap company with a market capitalisation of Rs 6,353.52 crore. That places it above many smaller industry names by size, while still keeping it well below the largest established pharma companies in the benchmark set.

Track Morepen Laboratories Share Price on Univest

UseMorepen Laboratories (MOREPENLAB) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, users can track Morepen Laboratories Share Price through live price updates, valuation ratios, peer comparison and sector benchmarks in one place.

Frequently Asked Questions

Why is Morepen Laboratories Share Price falling today?

Ans. The stock is down 6.25% at Rs 108.70 versus the previous close of Rs 115.95. The supplied data confirms the decline, but it does not provide a company-specific catalyst. The intraday range extended from Rs 104.4 to Rs 116.75.

What is Morepen Laboratories Share Price Today?

Ans. At the captured time, the stock was trading at Rs 108.70. It opened at Rs 116.15, touched a high of Rs 116.75 and a low of Rs 104.40. The previous close was Rs 115.95.

What is the market capitalisation of Morepen Laboratories?

Ans. The company’s market capitalisation is Rs 6,353.52 crore, and it is classified as a Mid Cap stock. The company operates in the Healthcare sector. Its P/E ratio is 45.21x. ROE is 7.96% and ROCE is 10.19%.

Is Morepen Laboratories expensive compared with its industry?

Ans. Based on the supplied benchmark, its P/E of 45.21 is above the industry median of 32.72, and its P/B of 4.88 is above the median of 3.05. The stock belongs to the Healthcare sector.

How profitable is Morepen Laboratories compared with peers?

Ans. ROE is 7.96% and ROCE is 10.19%. Both are below the same-industry median levels and below the five supplied large peers in the comparison table. Comparable listed companies include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals.

Where can investors track Morepen Laboratories Share Price updates?

Ans. Investors can track it on Univest for live price updates, valuation ratios, sector benchmarks and peer comparison. The previous close was Rs 115.95. The stock moved 6.25% lower during the session.